Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
As of close of business last night, Alkermes plc’s stock clocked out at $28.62, up 0.63% from its previous closing price of $28.44. In other words, the price has increased by $0.63 from its previous closing price. On the day, 2.21 million shares were traded. ALKS stock price reached its highest trading level at $28.77 during the session, while it also had its lowest trading level at $27.83.
Ratios:
To gain a deeper understanding of ALKS’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.25 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 9.63. For the most recent quarter (mrq), Quick Ratio is recorded 3.27 and its Current Ratio is at 3.67. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.04.
Upgrades & Downgrades
In the most recent recommendation for this company, Truist on November 11, 2025, initiated with a Buy rating and assigned the stock a target price of $50.
On September 26, 2025, RBC Capital Mkts Upgraded its rating to Outperform which previously was Sector Perform but kept the price unchanged to $44.
On September 03, 2025, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $44.Wells Fargo initiated its Overweight rating on September 03, 2025, with a $44 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 03 ’25 when Hopkinson Craig C. sold 3,748 shares for $30.00 per share. The transaction valued at 112,447 led to the insider holds 65,740 shares of the business.
Hopkinson Craig C. bought 3,748 shares of ALKS for $112,447 on Dec 03 ’25. On Dec 01 ’25, another insider, Hopkinson Craig C., who serves as the EVP R&D, Chief Medical Officer of the company, sold 4,000 shares for $29.30 each. As a result, the insider received 117,200 and left with 65,740 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ALKS now has a Market Capitalization of 4725663232 and an Enterprise Value of 3686147072. As of this moment, Alkermes’s Price-to-Earnings (P/E) ratio for their current fiscal year is 14.16, and their Forward P/E ratio for the next fiscal year is 17.45. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.11 while its Price-to-Book (P/B) ratio in mrq is 2.73. Its current Enterprise Value per Revenue stands at 2.423 whereas that against EBITDA is 9.483.
Stock Price History:
The Beta on a monthly basis for ALKS is 0.48, which has changed by -0.067541 over the last 52 weeks, in comparison to a change of 0.13042927 over the same period for the S&P500. Over the past 52 weeks, ALKS has reached a high of $36.45, while it has fallen to a 52-week low of $25.17. The 50-Day Moving Average of the stock is -5.91%, while the 200-Day Moving Average is calculated to be -4.47%.
Shares Statistics:
It appears that ALKS traded 2.36M shares on average per day over the past three months and 1706880 shares per day over the past ten days. A total of 165.10M shares are outstanding, with a floating share count of 161.42M. Insiders hold about 2.24% of the company’s shares, while institutions hold 103.94% stake in the company. Shares short for ALKS as of 1764288000 were 18829721 with a Short Ratio of 7.99, compared to 1761868800 on 15896950. Therefore, it implies a Short% of Shares Outstanding of 18829721 and a Short% of Float of 16.540001.
Earnings Estimates
. The current rating of Alkermes plc (ALKS) reflects the combined expertise of 4.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is $0.38, with high estimates of $0.38 and low estimates of $0.38.
Analysts are recommending an EPS of between $2.22 and $1.43 for the fiscal current year, implying an average EPS of $1.93. EPS for the following year is $2.16, with 2.0 analysts recommending between $2.32 and $2.0.
Revenue Estimates
In. The current quarter, 15 analysts expect revenue to total $378.57M. It ranges from a high estimate of $400.84M to a low estimate of $357M. As of. The current estimate, Alkermes plc’s year-ago sales were $429.99MFor the next quarter, 15 analysts are estimating revenue of $378.72M. There is a high estimate of $418.92M for the next quarter, whereas the lowest estimate is $329.83M.
A total of 15 analysts have provided revenue estimates for ALKS’s current fiscal year. The highest revenue estimate was $1.49B, while the lowest revenue estimate was $1.45B, resulting in an average revenue estimate of $1.47B. In the same quarter a year ago, actual revenue was $1.56BBased on 11 analysts’ estimates, the company’s revenue will be $1.8B in the next fiscal year. The high estimate is $1.91B and the low estimate is $1.54B.
